Type 2 diabetes mellitus development programs in the new regulatory environment with cardiovascular safety requirements

For type 2 diabetes mellitus treatment and clinical development, proper evaluation of cardiovascular risk has been required by regulatory agencies (eg, the US Food and Drug Administration) since cardiovascular safety is very important in this patient population. The US Food and Drug Administration i...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Fred, Stewart, Murray, Ye, June, DeMets, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516202/
https://www.ncbi.nlm.nih.gov/pubmed/26229496
http://dx.doi.org/10.2147/DMSO.S84005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4516202/
https://www.ncbi.nlm.nih.gov/pubmed/26229496
http://dx.doi.org/10.2147/DMSO.S84005

Ejemplares similares